Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes - Wikidata - wikimedia - TriplyDB

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

http://www.wikidata.org/entity/Q57076537

about

A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine HSV-2: in pursuit of a vaccine Prophylactic human papillomavirus vaccines Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future.A pooled analysis of the effect of condoms in preventing HSV-2 acquisition Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E Increase in rates of herpes simplex virus type 1 as a cause of anogenital herpes in western Sydney, Australia, between 1979 and 2003 Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey Seroepidemiology of Herpes Simplex virus type 1 and 2 in Western and Southern Switzerland in adults aged 25-74 in 1992-93: a population-based study Prevention of genital herpes in a guinea pig model using a glycoprotein D-specific single chain antibody as a microbicide Understanding natural herpes simplex virus immunity to inform next-generation vaccine design Optimal management of genital herpes: current perspectives Toll-like receptors: the swiss army knife of immunity and vaccine development Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions Tissue-resident memory T cells Bovine Herpes Virus 1 (BHV-1) and Herpes Simplex Virus Type 1 (HSV-1) Promote Survival of Latently Infected Sensory Neurons, in Part by Inhibiting Apoptosis Immune regulation of human herpesviruses and its implications for human transplantation The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa Phase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Naive and HSV-2-Infected Subjects Viral infections of the fetus and newborn infant Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands Genital Herpes: Insights into Sexually Transmitted Infectious Disease Novel agents and strategies to treat herpes simplex virus infections.Agents and strategies in development for improved management of herpes simplex virus infection and disease.Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda.HIV-1/HSV-2 co-infected adults in early HIV-1 infection have elevated CD4+ T cell counts.Genital herpes.New concepts in understanding genital herpes.Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.The herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects.Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women Liposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male mice.Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy Herpes simplex virus type 2 vaccines: new ground for optimism?Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein.Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes.Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2

P2860

Q21089976-8BF00086-F702-4C52-ADCE-9303B6441B1C Q21296712-EE0B35FE-9827-4197-81FE-8E0F87DFEBF9 Q21562177-30B5EF88-C220-416F-80F8-0735E0DCBE6A Q22306291-8923E05A-E0DF-4E11-BD19-F5394BB4458E Q24545449-AC3DA450-5687-4EEA-86BB-6CBA760FF1EC Q24600011-52AB8A56-ADBC-4D71-BEEB-F7FA1A69EDDF Q24631935-E2551BC2-A8EB-4AAB-8A58-973B89771B5A Q24646778-AC7882E3-0F1A-44FD-8C1D-40E96141D420 Q24654682-28202CCF-CF3F-4841-B790-41F4A851B3D3 Q24654706-1877EC0B-F586-4517-858C-F20A77207657 Q24791873-9F3BC558-2501-474A-A2AA-4AE387C56914 Q24803342-0C014892-7BE1-47EC-A339-4424B503F3A2 Q26741484-7AE895B6-179C-4DDE-8B68-3C018DF6650D Q26746041-0B58C9AC-4F9D-428E-8F24-458BEF2BDACB Q26746644-F73D6474-8C89-4379-A22A-E6DA6134FE53 Q26823594-AEA2AC3A-0761-40D1-A7A1-81493CB72970 Q26829804-EB7C3DB1-6BF6-4220-88D4-D38751E88DAB Q26864175-000EEFCB-1106-4ABF-B864-FB6AB660D74B Q26992146-AD70FCFA-A0DF-4511-8D09-ADDDDDDCAF6D Q27021292-B1DDCF9F-CC3C-4CC1-9A36-8A75EC4DBF9B Q27347896-7020BBA8-7893-4152-9DA1-58D6742EBEE0 Q27486108-D3BD26D6-4985-4F3A-8296-87D09E7E9DCC Q27488781-4D194D77-6D4C-4D7A-9BE1-EDF9B2240268 Q28972540-8A2C6F85-FF80-4460-A414-A3D94C30E8F9 Q30235026-D00FE991-1DC3-42B8-97DD-4ABB578483B0 Q30332444-DDEE4C69-813A-4E16-B7D4-C25FFE28454B Q30350341-4FAA20FC-362E-450F-BBFF-82C237DF0238 Q30396626-094DF143-1CF9-4A19-9843-E1DB718E9B37 Q33303686-D9509696-621C-4010-8668-CB49DE314716 Q33448071-7E513644-A7FD-48A1-8796-EDC6DF938A14 Q33582145-626974B8-BA15-4231-8F90-8470F241E6B8 Q33595097-F1BFD0C7-0F5A-4C3E-B26F-B02047C5416C Q33610941-E9F8FADD-D256-4B05-9CDD-7F28C76D9161 Q33663463-A199987B-695E-4845-AFAD-7CBAA7794FC4 Q33668447-8238DE6E-82E1-4056-8D9D-DE6D6280E267 Q33710019-CE50F28A-A588-48DB-809A-116A6CADBC19 Q33711912-B281A63E-11FC-456B-843B-98420D612ACE Q33724497-9E317658-7758-43C8-8CED-196416EDD8A7 Q33755236-31853753-1198-4C53-9DC5-C50878CF7DAF Q33812029-87B20BD8-AF0F-4829-96FC-60D3F5426868

P2860

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

http://www.wikidata.org/entity/Q57076537

description

im November 2002 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 01 November 2002

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2002

@uk

name

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

@en

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

@nl

type

label

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

@en

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

@nl

prefLabel

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

@en

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

@nl

P1433

Q57076537-89DDBF0D-17BD-456D-A7B0-06EC692CE452

P1476

Q57076537-B14836D7-823B-4C43-9825-E39B94F62B41

P2093

Q57076537-170AACDF-2FAB-4B02-92DA-FA1C1A6157CC

Q57076537-3E2A7E6A-3046-4434-99A3-8EA61FFFFDDC

Q57076537-452F761D-B275-416E-BBA9-8CE27F582B5F

Q57076537-4A88D595-42D0-474B-BE9C-7C62A65BBB1F

Q57076537-536FE567-F846-4AD1-9DD5-F85CAFFA3668

Q57076537-6214C416-D26A-417D-97B1-1FDF22D5168A

Q57076537-86327142-5CA6-4B32-B732-40B423E1AB0A

Q57076537-972C4BEB-CAAB-45B0-A205-4796123CF00F

Q57076537-CEC55799-E8E3-4282-A86E-B607BFB2FCE4

Q57076537-E1E1A6F3-0170-48CB-A2B4-321FA3561346

P304

Q57076537-367C8E14-FE81-4E8A-B71D-CA35A4CBF337

P31

Q57076537-64AC1928-D6BF-4BFE-A8AA-478AE5330BCF

P356

Q57076537-5F857EA5-4CB2-4B14-ACF1-5DAB871839B5

P407

Q57076537-5071A74E-C411-4ACA-BC3C-8833ED41467E

P433

Q57076537-F9D46528-AF61-46A0-82DC-A0698DC8363E

P478

Q57076537-44858946-CD53-493A-B12F-74E61A00247C

P50

Q57076537-2C51A9CB-215B-426F-938F-91E61C181097

Q57076537-CD7DA8E2-14BE-4FA7-8F66-A7279902F7E1

Q57076537-D53194A8-46BD-45D1-B958-668CAA455077

P577

Q57076537-47188900-26B5-4696-B292-653759C6076D

P698

Q57076537-3BD430F3-D5D8-4AEA-A412-3485CEF0A4EB

P356

P1433

The New England Journal of Medicine

P1476

Glycoprotein-D-adjuvant vaccine to prevent genital herpes

@en

P2093

David I Bernstein

http://www.w3.org/2001/XMLSchema#string

Fred Y Aoki

http://www.w3.org/2001/XMLSchema#string

Gary Dubin

http://www.w3.org/2001/XMLSchema#string

GlaxoSmithKline Herpes Vaccine Efficacy Study Group

http://www.w3.org/2001/XMLSchema#string

Lawrence R Stanberry

http://www.w3.org/2001/XMLSchema#string

Martine Denis

http://www.w3.org/2001/XMLSchema#string

Pierre Vandepapeliere

http://www.w3.org/2001/XMLSchema#string

Spotswood L Spruance

http://www.w3.org/2001/XMLSchema#string

Stephen Sacks

http://www.w3.org/2001/XMLSchema#string

Stephen Tyring

http://www.w3.org/2001/XMLSchema#string

P304

1652-1661

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA011915

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

347

http://www.w3.org/2001/XMLSchema#string

P50

Anthony L. Cunningham

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12444179

http://www.w3.org/2001/XMLSchema#string